OSLI Retina

September 2019

Issue link: http://osliretina.healio.com/i/1165509

Contents of this Issue

Navigation

Page 73 of 75

604 Ophthalmic Surgery, Lasers & Imaging Retina | Healio.com/OSLIRetina News and Notes News and Notes ONL Raises $3 Million in Financing to Advance Fas Inhibitor Study ONL Therapeutics (Ann Arbor, MI) will begin a first-in-human study of its Fas inhibitor for retinal diseases following the completion of $3 million in convert- ible note financing, according to a press release. ONL1204, a first-in-class small molecule Fas inhibitor, is designed to protect key retinal cells, including photoreceptors, from cell death that occurs in many retinal diseases and conditions and leads to vision loss. ONL is preparing ONL1204 for a phase 1 study in Australia for the treatment of retinal detachment. The company's management, current investors, and new investors participat- ed in the financing. Investors include Invest Michigan, the University of Michi- gan's Michigan Investment in New Technology Startups program, the Bioscienc- es Research & Commercialization Center, and the Capital Community Angels, as well as InFocus Capital Partners. "We are excited about the potential of ONL's Fas inhibition platform to ad- dress some major unmet medical needs in retinal disease," Ron Weiss, managing partner of InFocus Capital Partners, said in the release. "With its strong scientific foundation, compelling preclinical data and leadership team's depth of experi- ence, ONL Therapeutics is well-positioned to bring these therapies to market." Originally published on www.healio.com on August 23, 2019. Follow OSLIJournal OSLI Retina SLACK Incorporated 6900 Grove Road Thorofare, NJ 08086-9447 Phone: 856-994-9900 Email: osli@healio.com Healio.com/OSLIRetina Chief Content Officer Joan-Marie Stiglich, ELS EDITORIAL Senior Editorial Director David W. Mullin Executive Editor Cara Dickinson SALES Chief Commercial Officer Matthew J. Holland Group Sales Director, Eye Care Scott Wright Senior Account Manager Kathy Huntley National Account Manager Laura Renna Director, Sales Administration and Support Carolyn Boerner Sales Coordinator, Recruitment Jennifer Carroll Reprints/Eprints Licensing Opportunities: Sheridan Content Solutions scsreprints@sheridan.com DESIGN Creative Director Thomas Cavallaro Production and Circulation Director Cheryl McKeown Production Associate Ryan Davis The Wyanoke Group President Peter N. Slack Chief Operating Officer John C. Carter Chief Financial Officer Darrell Blood Senior Vice President Denise Mealey Chief Technology Officer Linda Baker Ophthalmic Surgery, Lasers & Imaging Retina® (ISSN-2325-8160, Canadian BN-12978 0466 RT ) is published 12 times per year by SLACK Incorporated®, and is an official publication of ARVO/ISIE. Publication Office: SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Telephone (856) 848-1000. Printed in the USA. Periodicals Class Postage Paid at Deptford, NJ 08096 and at additional mailing offices. Contents copyrighted by SLACK Incorporated®, 2019. All rights reserved. No part of this publication may be reproduced with- out prior written consent of the publisher. All requests to reprint or use material published herein should be directed to the Request Permissions link on every article page at Healio.com/ophthalmology/journals/osli. Subscription rates in the U.S. and possessions: Individuals: One year—print $222, electronic only: $197. Institutional: One year—$692. Residents and fellows: $111 for one year (a letter of certification indicating residency of the subscriber is required). Canada add 5% GST, all other countries add $71 per year. All subscriptions, without exception, will start with the first issue pub- lished after the order is received. Single copies and back issues, when available, are $99. Payment must accompany order. Subscrip- tion requests should be addressed to the publisher. Change of Address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new ad- dresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Duplicate copies will not be sent to re- place ones undelivered through failure to notify the publisher of change of address. POSTMASTER: Send Form 3547 to Ophthalmic Surgery, Lasers & Imaging Retina®, SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Articles are intended for informational purposes only and should not be used as the basis of patient treatment. All opinions expressed by authors and quoted sources are their own and do not necessarily reflect the opinions of the editors, publisher, or editorial boards of SLACK Incorporated®. The acceptance of advertising in no way implies endorsement by the editors, publisher, or editorial boards of SLACK Incorporated®. See website for print and web advertising policy. Readers with queries about the Journal's policies on error correction, version control, journal of record, ancillary material, or archiving should contact osli@healio.com. The Journal staff have no financial relationships to disclose. Financial disclosures for the Editor and members of the Editorial Board are on file with the editorial office. Indexed in: Medline/PubMed, ProQuest, EMCare, EMBASE, Science Citation Index, Current Contents/Clinical Medicine, BioEn- gineering Abstracts, CAB Abstracts, and SCOPUS.

Articles in this issue

Links on this page

Archives of this issue

view archives of OSLI Retina - September 2019